BACKGROUND: Recurrent tuberculosis disease occurs within 2 years in as few as 1% and as many as 29% of individuals successfully treated for multidrug-resistant (MDR) tuberculosis. A better understanding of treatment-related factors associated with an elevated risk of recurrent tuberculosis after cure is urgently needed to optimize MDR tuberculosis therapy. METHODS: We conducted a retrospective cohort study among adults successfully treated for MDR tuberculosis in Peru. We used multivariable Cox proportional hazards regression analysis to examine whether receipt of an aggressive MDR tuberculosis regimen for ≥18 months following sputum conversion from positive to negative was associated with a reduced rate of recurrent tuberculosis. RESULTS: Among 402 patients, the median duration of follow-up was 40.5 months (interquartile range, 21.2-53.4). Receipt of an aggressive MDR tuberculosis regimen for ≥18 months following sputum conversion was associated with a lower risk of recurrent tuberculosis (hazard ratio, 0.40 [95% confidence interval, 0.17-0.96]; P = .04). A baseline diagnosis of diabetes mellitus also predicted recurrent tuberculosis (hazard ratio, 10.47 [95% confidence interval, 2.17-50.60]; P = .004). CONCLUSIONS: Individuals who received an aggressive MDR tuberculosis regimen for ≥18 months following sputum conversion experienced a lower rate of recurrence after cure. Efforts to ensure that an aggressive regimen is accessible to all patients with MDR tuberculosis, such as minimization of sequential ineffective regimens, expanded drug access, and development of new MDR tuberculosis compounds, are critical to reducing tuberculosis recurrence in this population. Patients with diabetes mellitus should be carefully managed during initial treatment and followed closely for recurrent disease.
BACKGROUND: Recurrent tuberculosis disease occurs within 2 years in as few as 1% and as many as 29% of individuals successfully treated for multidrug-resistant (MDR) tuberculosis. A better understanding of treatment-related factors associated with an elevated risk of recurrent tuberculosis after cure is urgently needed to optimize MDR tuberculosis therapy. METHODS: We conducted a retrospective cohort study among adults successfully treated for MDR tuberculosis in Peru. We used multivariable Cox proportional hazards regression analysis to examine whether receipt of an aggressive MDR tuberculosis regimen for ≥18 months following sputum conversion from positive to negative was associated with a reduced rate of recurrent tuberculosis. RESULTS: Among 402 patients, the median duration of follow-up was 40.5 months (interquartile range, 21.2-53.4). Receipt of an aggressive MDR tuberculosis regimen for ≥18 months following sputum conversion was associated with a lower risk of recurrent tuberculosis (hazard ratio, 0.40 [95% confidence interval, 0.17-0.96]; P = .04). A baseline diagnosis of diabetes mellitus also predicted recurrent tuberculosis (hazard ratio, 10.47 [95% confidence interval, 2.17-50.60]; P = .004). CONCLUSIONS: Individuals who received an aggressive MDR tuberculosis regimen for ≥18 months following sputum conversion experienced a lower rate of recurrence after cure. Efforts to ensure that an aggressive regimen is accessible to all patients with MDR tuberculosis, such as minimization of sequential ineffective regimens, expanded drug access, and development of new MDR tuberculosis compounds, are critical to reducing tuberculosis recurrence in this population. Patients with diabetes mellitus should be carefully managed during initial treatment and followed closely for recurrent disease.
Authors: K F Laserson; L E Thorpe; V Leimane; K Weyer; C D Mitnick; V Riekstina; E Zarovska; M L Rich; H S F Fraser; E Alarcón; J P Cegielski; M Grzemska; R Gupta; M Espinal Journal: Int J Tuberc Lung Dis Date: 2005-06 Impact factor: 2.373
Authors: L L Han; A Sloutsky; R Canales; V Naroditskaya; S S Shin; K J Seung; R Timperi; M C Becerra Journal: Int J Tuberc Lung Dis Date: 2005-07 Impact factor: 2.373
Authors: Jose G Somocurcio; Alfredo Sotomayor; Sonya Shin; Silvia Portilla; Maria Valcarcel; Dalia Guerra; Jennifer Furin Journal: Thorax Date: 2006-08-23 Impact factor: 9.139
Authors: K Chalco; D Y Wu; L Mestanza; M Muñoz; K Llaro; D Guerra; E Palacios; J Furin; S Shin; R Sapag Journal: Int Nurs Rev Date: 2006-12 Impact factor: 2.871
Authors: V Balaji; Peter Daley; Alok Azad Anand; Thambu Sudarsanam; Joy Sarojini Michael; Rani Diana Sahni; Poorvi Chordia; Ige Abraham George; Kurien Thomas; Alka Ganesh; K R John; Dilip Mathai Journal: PLoS One Date: 2010-03-04 Impact factor: 3.240
Authors: Guang Xue He; Yan Guang Xie; Li Xia Wang; Martien W Borgdorff; Marieke J van der Werf; Ji Huan Fan; Xing Lu Yan; Fa Bin Li; Xue Zhi Zhang; Yan Lin Zhao; Susan van den Hof Journal: PLoS One Date: 2010-05-24 Impact factor: 3.240
Authors: Susan P Fisher-Hoch; Erin Whitney; Joseph B McCormick; Gonzalo Crespo; Brian Smith; Mohammad H Rahbar; Blanca I Restrepo Journal: Scand J Infect Dis Date: 2008
Authors: Molly F Franke; Mercedes C Becerra; Dylan B Tierney; Michael L Rich; Cesar Bonilla; Jaime Bayona; Megan M McLaughlin; Carole D Mitnick Journal: Ann Am Thorac Soc Date: 2015-05
Authors: Sarah K Brode; Robert Varadi; Jane McNamee; Nina Malek; Sharon Stewart; Frances B Jamieson; Monica Avendano Journal: Can Respir J Date: 2014-12-10 Impact factor: 2.409
Authors: A M W Efsen; A Schultze; R F Miller; A Panteleev; A Skrahin; D N Podlekareva; J M Miro; E Girardi; H Furrer; M H Losso; J Toibaro; J A Caylà; A Mocroft; J D Lundgren; F A Post; O Kirk Journal: J Infect Date: 2017-10-20 Impact factor: 6.072
Authors: Gustavo E Velásquez; Mercedes C Becerra; Irina Y Gelmanova; Alexander D Pasechnikov; Askar Yedilbayev; Sonya S Shin; Yevgeny G Andreev; Galina Yanova; Sidney S Atwood; Carole D Mitnick; Molly F Franke; Michael L Rich; Salmaan Keshavjee Journal: Clin Infect Dis Date: 2014-04-11 Impact factor: 9.079
Authors: Nivedita Lahiri; Rupal R Shah; Emilie Layre; David Young; Chris Ford; Megan B Murray; Sarah M Fortune; D Branch Moody Journal: J Biol Chem Date: 2016-05-10 Impact factor: 5.157
Authors: J Peter Cegielski; Ekaterina Kurbatova; Martie van der Walt; Jeannette Brand; Julia Ershova; Thelma Tupasi; Janice Campos Caoili; Tracy Dalton; Carmen Contreras; Martin Yagui; Jaime Bayona; Charlotte Kvasnovsky; Vaira Leimane; Liga Kuksa; Michael P Chen; Laura E Via; Soo Hee Hwang; Melanie Wolfgang; Grigory V Volchenkov; Tatiana Somova; Sarah E Smith; Somsak Akksilp; Wanpen Wattanaamornkiet; Hee Jin Kim; Chang-Ki Kim; Boris Y Kazennyy; Tatiana Khorosheva; Kai Kliiman; Piret Viiklepp; Ruwen Jou; Angela Song-En Huang; Irina A Vasilyeva; Olga V Demikhova; Joey Lancaster; Ronel Odendaal; Lois Diem; Therese C Perez; Tarcela Gler; Kathrine Tan; Cesar Bonilla; Oswaldo Jave; Luis Asencios; Gloria Yale; Carmen Suarez; Allison Taylor Walker; Inga Norvaisha; Girts Skenders; Ingrida Sture; Vija Riekstina; Andra Cirule; Erika Sigman; Sang-Nae Cho; Ying Cai; Seokyong Eum; Jongseok Lee; Seungkyu Park; Doosoo Jeon; Isdore C Shamputa; Beverly Metchock; Tatiana Kuznetsova; Rattanawadee Akksilp; Wanlaya Sitti; Jirapan Inyapong; Elena V Kiryanova; Irina Degtyareva; Evgenia S Nemtsova; Klavdia Levina; Manfred Danilovits; Tiina Kummik; Yung-Chao Lei; Wei-Lun Huang; Vladislav V Erokhin; Larisa N Chernousova; Sofia N Andreevskaya; Elena E Larionova; Tatyana G Smirnova Journal: Clin Infect Dis Date: 2015-10-27 Impact factor: 9.079
Authors: Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon Journal: Clin Infect Dis Date: 2016-08-10 Impact factor: 9.079